NGNE Stock Analysis: Buy, Sell, or Hold?
NGNE - Neurogene, Inc. Common Stock
$17.66
-1.23 (-6.51%)
▼
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Mar 23, 2026
Get Alerted When NGNE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: NGNE shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: NGNE shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: NGNE is currently trading at $17.66, which is considered oversold relative to its 30-day fair value range of $17.70 to $20.04.
Technical Outlook: Technically, NGNE is in a downtrend. Immediate support is located at $16.93, while resistance sits at $20.44. Short-term momentum is weak, with the stock down 6.5% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $57.20 (+223.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NGNE is in a downtrend. Immediate support is located at $16.93, while resistance sits at $20.44. Short-term momentum is weak, with the stock down 6.5% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $57.20 (+223.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$17.70 -
$20.04
Company Quality Score
54/100
(HOLD)
Options IV Signal
46th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
75.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 46th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.5%)
- BULLISH: Trading 223.9% below Wall St target ($57.20)
Fair Price Analysis
30-Day Fair Range
$17.70 -
$20.04
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$2.29
(13.0%)
Support & Resistance Levels
Support Level
$16.94
Resistance Level
$20.44
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-3.86
Wall Street Target
$57.20
(+223.9%)
Last updated: February 01, 2026 7:58 PM ET
Data refreshes hourly during market hours. Next update: 8:58 PM
Data refreshes hourly during market hours. Next update: 8:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NGNE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 59 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$140 | 59 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
